Table 2.
Performance of EHR extraction of treatment regimen in Multiple myeloma
| Treatment regimen | MM patients, n | Accuracy, n (%) |
|---|---|---|
| Anti-CD38 based therapy | 55 | 53 (96) |
| Proteasome inhibitor and IMID-based | 22 | 22 (100) |
| Proteasome inhibitor-based therapy | 16 | 16 (100) |
| IMID-based therapy | 37 | 34 (92) |
| Immunotherapy | ||
| Bispecific antibody therapy | 17 | 17 (100) |
| CAR-T cell therapy | 5 | 5 (100) |
| Other | 10 | 9 (90) |
| Hematopoietic stem cell transplantation | 36 | 36 (100) |
| Total | 198 | 192 (97) |
Anti-CD38 based therapy: daratumumab, bortezomib, lenalidomide, dexamethasone (D-VRd); daratumumab, bortezomib, thalidomide, dexamethasone (D-VTd); daratumumab, bortezomib, cyclophosphamide, dexamethasone (D-VCd); daratumumab, bortezomib, melphalan, prednisone (D-VMP); daratumumab, bortezomib, dexamethasone (D-Vd); daratumumab, lenalidomide, dexamethasone (D-Rd); daratumumab, pomalidomide, dexamethasone (D-Pd); daratumumab monotherapy (D-mono), isatuximab, carfilzomib, lenalidomide, dexamethasone (Isa-KRd); isatuximab, carfilzomib, dexamethasone (Isa-Kd), isatuximab, pomalidomide, dexamethasone (Isa-Pd). Proteasome inhibitor and IMID-based: bortezomib, lenalidomide, dexamethasone (VRd); bortezomib, thalidomide, dexamethasone (VTd); bortezomib, cyclophosphamide, dexamethasone (VCd), pomalidomide, bortezomib, dexamethasone (Pom-Vd), ixazomib, lenalidomide, dexamethasone (IRd). Proteasome inhibitor-based therapy: bortezomib, dexamethasone (Vd), carfilzomib, lenalidomide, dexamethasone (KRd), carfilzomib, dexamethasone (Kd). IMID-based therapy: pomalidomide, cyclophosphamide, dexamethasone (PCd), lenalidomide, dexamethasone (Rd), pomalidomide, dexamethasone (Pd), pomalidomide monotherapy (P-mono), lenalidomide maintenance, iberdomide maintenance. Bispecific antibody therapy: talquetamab, pomalidomdide, daratumumab (Tal-PD), teclistamab (Tec), elranatamab, dexamethasone (Elr), trial medication (Other). Other: elotuzumab, pomalidomide, dexamethasone (Epd), elotuzumab, lenalidomide, dexamethasone (ERd), melphalan, Bridging therapy. Hematopoietic stem cell transplantation: Auto-SCT, Allo-SCT. Abbreviation: MM, multiple myeloma; IMID, immunomodulatory drugs.